At the conference, AmerisourceBergen leaders underscored the importance of collaboration and innovation in the delivery of pharmaceutical care, as well as recent Company investments in technology and value-creating innovations, which best position the organization to support manufacturers’ evolving commercialization needs and drive improved patient outcomes. Company leadership also discussed the organization’s new operating model that was designed to simplify access to AmerisourceBergen’s broad portfolio of services.
“The pharmaceutical industry is evolving as a new wave of complex, novel specialty therapies are offering significant promise, but also new challenges. As healthcare continues to transform, we are evolving at AmerisourceBergen to better provide best-in-class solutions aligned with our customers’ changing needs,” said Steve Collis, Chairman, President and CEO of AmerisourceBergen. “It is our responsibility to bring efficiency and innovation to the pharmaceutical supply chain, so we can all ensure people have access to both quality care and the medications they need in a convenient, local and affordable way.”
Throughout the conference, manufacturers and AmerisourceBergen had the opportunity to discuss critical industry matters, such as the growing specialty product pipeline and integrated commercialization approaches for emerging therapies, such as cell and gene and biosimilars.
During his general session remarks, Jim Cleary, Group President of Global Commercialization Services and Animal Health at AmerisourceBergen, announced the launch of Lash Group’s new patient support technology platform, Fusion, which will help manufacturers achieve three major goals: increase speed to therapy, improve patient and provider outcomes and generate actionable insights. The end-to-end solution combines dozens of best-in-class technologies, a proprietary, advanced data model that provides a personalized and seamless experience for patients, providers and manufacturers.
AmerisourceBergen also recognized several individuals and companies for their leadership in driving innovation and shaping healthcare delivery, including:
Excellence in Product Value & Innovation: Tesaro
Manufacturer Relations Leadership: Mark Davis, Bayer Consumer
Excellence in Product Value & Innovation: Zydus Pharmaceuticals
Excellence in Product Value & Innovation: GSK for Rx OTC
Commitment to Patient Care: The Alliance (Sanofi & Regeneron)
Manufacturer Relations Leadership: John Crawford, Apotex
Shaping Healthcare Delivery: Northwestern Memorial Hospital
ThinkLive is an annual conference that is focused on providing pharmaceutical manufacturers with integrated, forward-thinking and patient-centric solutions to help maximize success at every stage of the product life cycle.
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 20,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500, with more than $145 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com